City Therapeutics Takes Next-Gen RNAi Tech to November Investor Conferences

CAMBRIDGE, Mass. – November 03, 2026 — The landscape of genetic medicine is shifting rapidly, and the next frontier of RNA interference (RNAi) is stepping into the institutional spotlight. City Therapeutics, a clinical-stage biotechnology company that recently executed one of the most closely watched initial public offerings of the year, announced today that its executive management team will present at two premier healthcare investor conferences this November.

The company is scheduled to host a fireside chat at the Stifel 2026 Healthcare Conference in New York on November 10, followed by a formal presentation at the Jefferies Global Healthcare Conference in London on November 16. Both appearances will be webcast live on the company's investor relations portal.

While routine conference appearances are standard practice for publicly traded biotechs, City Therapeutics' upcoming presentations carry outsized weight. Fresh off a $230 million IPO that closed in mid-October, the company is tasked with proving that its proprietary platform can overcome the historical limitations of first-generation RNAi therapies. For healthcare investors and patient advocates alike, these November sessions will serve as a critical barometer of the company's clinical execution and strategic runway.

The Institutional Spotlight: What Investors Want to See

When City Therapeutics leadership takes the stage in New York and London, institutional investors will be listening for specific clinical validation metrics. The company's lead asset, CITY-FXI, is currently in a Phase 1 first-in-human study targeting thromboembolic diseases.

For decades, the pharmaceutical industry has chased the holy grail of cardiology: an antithrombotic agent that prevents catastrophic blood clots without leaving patients vulnerable to life-threatening bleeding events. Factor XI (FXI) inhibition has emerged as a highly competitive pathway to achieve this, aiming to uncouple hemostasis from thrombosis.

Initial data from the first three cohorts of healthy volunteers in the CITY-FXI trial have been highly encouraging. The drug has been generally well-tolerated, demonstrating an FXI knockdown ranging from over 60 percent at lower doses to a robust 85 percent three weeks after a single 150 mg subcutaneous dose. With additional Phase 1 single-ascending dose (SAD) data expected in late 2026, analysts anticipate that management will use the Stifel and Jefferies conferences to set the stage for these upcoming readouts.

Investors will be particularly focused on the timeline for the planned Phase 2 study in total knee arthroplasty (TKA), slated for mid-2027. Demonstrating durable, safe knockdown of Factor XI will be essential for City Therapeutics to differentiate itself in a crowded field that includes other RNAi developers, antisense oligonucleotide approaches, and monoclonal antibodies.

Pushing RNAi Beyond the Liver

To understand the strategic positioning of City Therapeutics, one must look at the evolution of the RNAi space. The first wave of RNA interference therapies, pioneered by industry giants like Alnylam Pharmaceuticals, successfully utilized GalNAc conjugation to deliver gene-silencing payloads directly to the liver. However, expanding targeted delivery to the central nervous system, adipose tissue, or the eye has remained a formidable biological bottleneck.

City Therapeutics aims to break this bottleneck with its proprietary "City Platform." The technology integrates AI and machine learning-enabled molecular design to create "cityRNA triggers"—engineered molecules designed to be more potent and specific than conventional siRNA. More importantly, the company is pairing these triggers with novel tissue-targeting ligands.

While CITY-FXI utilizes proven GalNAc liver targeting, the company's broader ambition is to reach extrahepatic tissues using proprietary LRP1 ligands. This technological pivot is what separates a derivative biotech from a disruptive one.

Adding immense credibility to this ambitious roadmap is the presence of John Maraganore as co-founder and executive chairman. As the founding CEO of Alnylam, Maraganore is widely regarded as the architect of the commercial RNAi industry. Industry insiders suggest that his backing of City Therapeutics as the "next generation" of RNAi is a primary driver of the company's strong institutional support and successful IPO. When management speaks at Jefferies and Stifel, they will be speaking with the implicit endorsement of one of the sector's most successful pioneers.

Pipeline Milestones and Patient Impact

Beyond cardiovascular indications, City Therapeutics is applying its platform to areas of profound unmet medical need, a strategy that aligns business viability with significant human impact.

The company's second lead candidate, CITY-RBP4, is currently in a Phase 1 adaptive study for Stargardt disease, a genetic eye disorder that causes progressive vision loss and currently has no approved treatments. By silencing the RBP4 gene, the therapy aims to halt the toxic accumulation of retinoids in the eye that drives macular degeneration. Preclinical data presented earlier this year demonstrated potent and durable silencing, and the Phase 1 trial began dosing in September 2026.

Management is expected to outline the capital allocation for this program, utilizing roughly $20 million of the recent IPO proceeds to push CITY-RBP4 through early testing and prepare for a Phase 2 trial in geographic atrophy planned for late 2027. For patients facing progressive blindness, the acceleration of this clinical timeline is a beacon of hope.

Additionally, the company is advancing CITY-TFR2 for chronic disease-associated anemia. With an investigator-initiated trial expected to launch in China in late 2026 and a company-sponsored Phase 1/2 study planned for early 2027, City Therapeutics is rapidly expanding its clinical footprint across multiple therapeutic areas.

Capital Allocation and Strategic Alliances

From a financial perspective, City Therapeutics enters the November conference circuit in an enviable position. The $230 million raised in October provides an estimated cash runway extending into late 2028. This allows the company to operate from a position of strength, funding its aggressive clinical timeline without the immediate pressure of returning to the capital markets.

The company is also bolstered by existing research collaborations with Bausch + Lomb for ocular RNAi therapeutics and Biogen for central nervous system diseases. These partnerships not only provide non-dilutive capital—generating $6.4 million in collaboration revenue in the first half of 2026 alone—but also serve as external validation of the City Platform's potential to reach tissues beyond the liver.

As the biotech sector watches the Stifel and Jefferies webcasts this November, the narrative will be clear. City Therapeutics is no longer just a promising startup with a novel scientific theory. With a fortified balance sheet, a rapidly advancing clinical pipeline, and a leadership team steeped in RNAi history, the company is actively laying the groundwork to define the next decade of genetic medicine.